Positive results for Avexa
Monday, 16 March, 2009
Melbourne biotech Avexa has reported positive results from its ongoing Phase IIb trial of apricitabine (ATC) in patients with HIV.
Apricitabine is also in Phase III trials for HIV patients with resistance to common antiretrovirals. Interim results in this trial are expected shortly.
The Phase IIb trial is an open label trial for people who have failed previous HIV treatments such as 3TC. After almost two years on the trial, no resistance to ATC has been identified and no serious adverse events have been reported.
Over 85 per cent of patients have HIV loads below detectable levels and CD4 cells on average were over 500 microlitres, the company said.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
